Company Analysis
Sign in

Forte Biosciences, Inc. (FBRX)

FBRX · Pharmaceutical Preparations · Dallas, TX · filing with the SEC since 2007
Full chart Alerts Compare
Grade4.8
◀ Past 3.3● Present 3.7▶ Future 6.8
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

13 patents granted to the 5 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Forte Biosciences, Inc.’s names, not what it holds today.

Patents granted
13
13 utility, 1976 to Dec 31, 2025
Granted in 2025
none
in the last year the record reads
Applications published
31
2 of them in 2025
Names they are printed under
5
a former name, a subsidiary, its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name5 counted
Tocagen Inc. a former name
US, as the owner printed on each patent
12 granted
14 published
Tocagen Inc. a former name
named as the applicant on its applications, in US
0 granted
10 published
Forte Subsidiary, Inc. a subsidiary
named as the applicant on its applications, in US
0 granted
4 published
FORTE SUBSIDIARY, INC. a subsidiary
US, as the owner printed on each patent
1 granted
1 published
Forte Biosciences, Inc its own name
named as the applicant on its applications, in US
0 granted
2 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Apr 13, 202110,973,841Compositions for the treatment of skin conditionsPharmaceuticalsFORTE SUBSIDIARY, INC.
Oct 22, 201910,449,194Formulations of 5-fluorocytosine and uses thereofPharmaceuticalsTocagen Inc.
Sep 10, 201910,407,666Recombinant vectorsPharmaceuticalsTocagen Inc.
Jun 11, 201910,316,333Producer cells for replication competent retroviral vectorsPharmaceuticalsTocagen Inc.
Jul 31, 201810,035,983Gene therapy vectors and cytosine deaminasesBiotechnologyTocagen Inc.
Feb 13, 20189,889,133Formulations of 5-fluorocytosine and uses thereofPharmaceuticalsTocagen Inc.
Aug 15, 20179,732,326Recombinant vectorsPharmaceuticalsTocagen Inc.
Jun 6, 20179,669,049Compositions comprising gamma retrovirus vectors and methods of treating proliferative disordersPharmaceuticalsTocagen Inc.
May 30, 20179,663,834Retrovirus detectionBiotechnologyTocagen Inc.
May 9, 20179,642,921Cancer combination therapy and recombinant vectorsPharmaceuticalsTocagen Inc.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Oct 9, 20252025/0313642METHODS OF TREATING ACUTE AND CHRONIC GRAFT VERSUS HOST DISEASEPharmaceuticalsForte Subsidiary, Inc.
Aug 14, 20252025/0257143ANTI-CD122 ANTIBODIES AND USES THEREOFBiotechnologyForte Subsidiary, Inc.
Aug 5, 20212021/0236562COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONSPharmaceuticalsFORTE SUBSIDIARY, INC.
Jul 29, 20212021/0228650COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONSPharmaceuticalsForte Subsidiary, Inc.
Jun 24, 20212021/0186998COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONSPharmaceuticalsForte Subsidiary, Inc.
Sep 10, 20202020/0281929FORMULATIONS OF 5-FLUOROCYTOSINE AND USES THEREOFPharmaceuticalsTocagen Inc. · patent 11,191,764 granted from it
Jul 30, 20202020/0239858RECOMBINANT VECTORSPharmaceuticalsTocagen Inc.
Nov 21, 20192019/0352667PRODUCER CELLS FOR REPLICATION COMPETENT RETROVIRAL VECTORSPharmaceuticalsTocagen Inc. · patent 11,060,112 granted from it
Nov 14, 20192019/0343856COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONSPharmaceuticalsForte Biosciences, Inc · patent 10,973,841 granted from it
Oct 24, 20192019/0321416COMPOSITIONS FOR THE TREATMENT OF SKIN CONDITIONSPharmaceuticalsForte Biosciences, Inc
What it applied for, 2024 to 2025: Biotechnology 1 · Pharmaceuticals 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton FBRX · research, not advice